Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Deep Vein Thrombosis (DVT) Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Deep Vein Thrombosis (DVT) Overview | 8 | 1 |
| Pipeline Products for Deep Vein Thrombosis (DVT) Comparative Analysis | 9 | 1 |
| Deep Vein Thrombosis (DVT) Therapeutics under Development by Companies | 10 | 1 |
| Deep Vein Thrombosis (DVT) Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Deep Vein Thrombosis (DVT) Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Deep Vein Thrombosis (DVT) Products under Development by Companies | 15 | 1 |
| Deep Vein Thrombosis (DVT) Products under Investigation by Universities/Institutes | 16 | 1 |
| Deep Vein Thrombosis (DVT) Companies Involved in Therapeutics Development | 17 | 6 |
| 3SBio Inc. | 17 | 1 |
| Dong-A Socio Holdings Co. Ltd. | 18 | 1 |
| F. Hoffmann-La Roche Ltd. | 19 | 1 |
| Generex Biotechnology Corporation | 20 | 1 |
| Laboratorios Farmaceuticos Rovi, S.A. | 21 | 1 |
| Pharmathen Pharmaceuticals S.A. | 22 | 1 |
| Deep Vein Thrombosis (DVT) Therapeutics Assessment | 23 | 9 |
| Assessment by Monotherapy Products | 23 | 1 |
| Assessment by Target | 24 | 2 |
| Assessment by Mechanism of Action | 26 | 2 |
| Assessment by Route of Administration | 28 | 2 |
| Assessment by Molecule Type | 30 | 2 |
| Drug Profiles | 32 | 10 |
| Antisense RNAi Oligonucleotide for Deep Vein Thrombosis Drug Profile | 32 | 1 |
| ARC-15105 Drug Profile | 33 | 1 |
| CM-20201 Drug Profile | 34 | 1 |
| enoxaparin sodium biosimilar Drug Profile | 35 | 1 |
| enoxaparin sodium biosimilar Drug Profile | 36 | 1 |
| enoxaparin sodium biosimilar Drug Profile | 37 | 1 |
| fondaparinux sodium Drug Profile | 38 | 1 |
| Polysaccharide to Inhibit Factor X for Deep Vein Thrombosis Drug Profile | 39 | 1 |
| STP-023725 Drug Profile | 40 | 1 |
| TRX-1 Drug Profile | 41 | 1 |
| Deep Vein Thrombosis (DVT) Dormant Projects | 42 | 1 |
| Deep Vein Thrombosis (DVT) Discontinued Products | 43 | 1 |
| Deep Vein Thrombosis (DVT) Product Development Milestones | 44 | 17 |
| Featured News &Press Releases | 44 | 1 |
| Aug 22, 2016: New Real-World Evidence on Venous and Arterial Blood Clot Management including Bayer s Xarelto Accepted for Presentation at ESC Congress 2016 | 44 | 3 |
| May 18, 2016: Janssen to Present Data on Rivaroxaban at the 2016 American Society of Clinical Oncology Annual Meeting | 47 | 1 |
| Apr 25, 2016: Patent Term for Rivaroxaban Extended in US | 48 | 1 |
| Jan 18, 2016: Lawsuitsettlementnews.com Says Xarelto Lawsuits Rise as Court Begins Process to Select Cases for Initial Bellwether Trials | 48 | 1 |
| Dec 10, 2015: AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism, VTE-Related Death and Major Bleeding in Deep Vein Thrombosis and Pulmonary Embolism Patients Treated with Eliquis (apixaban) or Conventional Therapy | 49 | 1 |
| Dec 07, 2015: Real-World Data Confirms Safety and Efficacy Profile of XARELTO, With Shorter Hospital Stays, for the Treatment of Deep Vein Thrombosis | 50 | 1 |
| Nov 30, 2015: New Data from Bayer s Portfolio in Thrombosis to be Presented at ASH 2015 | 51 | 1 |
| Nov 06, 2015: Important Global Data from XARELTO EXPLORER Cardiovascular Research Program Highlighted in 17 Presentations at the American Heart Association Scientific Sessions 2015 | 51 | 2 |
| Nov 05, 2015: Janssen to Present Posters on rivaroxaban at the 2015 American Society of Hematology Annual Meeting | 53 | 1 |
| May 04, 2015: Bayer s Xarelto Approved in China for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation and for the Treatment of Deep Vein Thrombosis | 54 | 1 |
| Apr 07, 2015: Xarelto Litigation Update: Legal-Bay Lawsuit Settlement Funding Reports Issuance of New Court Documents | 55 | 1 |
| Mar 30, 2015: New Study Shows Reduced Hospital Admissions and Costs for Deep Vein Thrombosis Patients Treated with XARELTO Compared to Traditional Therapy, With No Difference in Subsequent Hospital Visits | 55 | 2 |
| Mar 02, 2015: Findings to be Presented at Annual Scientific Session of the American College of Cardiology About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO | 57 | 1 |
| Nov 26, 2014: ELIQUIS approved for treatment of venous thromboembolic events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and prevention of recurrent DVT and PE | 58 | 1 |
| Aug 22, 2014: U.S. FDA Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism, and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy | 59 | 2 |
| Appendix | 61 | 2 |
| Methodology | 61 | 1 |
| Coverage | 61 | 1 |
| Secondary Research | 61 | 1 |
| Primary Research | 61 | 1 |
| Expert Panel Validation | 61 | 1 |
| Contact Us | 61 | 1 |
| Disclaimer | 62 | 1 |
